"BioNTech announced it was closing production sites in Germany and Singapore, cutting costs after a 532 million ($627 million) net quarterly loss and bracing for the departure of its visionary founders, Ugur Sahin and Ozlem Tureci."
"Financial analysts say that BioNTech's problems stem from the predictable end of a temporary COVID windfall, which provided tens of billions of euros in revenue since late 2020."
"Demand for BioNTech's COVID vaccine Comirnaty evaporated faster than expected, with first-quarter 2026 revenues dropping to 118 million, down 35% from the same quarter last year."
BioNTech, known for its mRNA COVID-19 vaccine, is experiencing financial difficulties after a period of success. The company announced job cuts and site closures following a substantial quarterly loss. Analysts attribute these challenges to the end of the COVID vaccine demand surge, high operational costs, and reliance on a single product. Revenue from the COVID vaccine has significantly declined, prompting concerns about the company's future and sustainability in the biotechnology sector.
Read at www.dw.com
Unable to calculate read time
Collection
[
|
...
]